Skip to main content

Qiagen Reports Increase in Q3 Revenue, R&D Spending, Net Income

NEW YORK, Oct. 28 - Qiagen today reported strong third-quarter revenue growth, an in increase in R&D spending, and a slight jump in net income.


For the period ended Sept. 30, Qiagen said net sales were $76.9 million compared with $63.3 million during the same quarter one year ago.


R&D spending in the third quarter increased to $7.3 million from $6.1 million year over year.


Net income for the quarter increased $7.3 million, or $.05 per share, from $6.2 million, or $.04 in the year-ago quarter, the company said.


Qiagen said it has roughly $51.8 million in cash and cash equivalents as of Sept. 30.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.